BioNTech SE(BNTX) - 2023 Q2 - Earnings Call Transcript

Ugur Sahin on innate -- quick initiation of innate response and hindering the full capacity of self-amplifying mRNA. And we are working on an improved approach of overcoming this innate immune response limitation on a adapted monovalent amplifying mRNA platform, which combines two advantages, the advantage of safety. Bill Maughan Thank you. We will now go to the next question. And your next question comes from the line of Ellie Merle from UBS. Please go ahead. Ozlem Tureci Operator Thank you. Thank you. We ...